Compare TG Therapeutics Inc (TGTX) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Unity Software Inc — how do they compare? TG Therapeutics Inc trades at $54.98 (market cap $8.16B), while Unity Software Inc trades at $46.96 (market cap $20.20B). The key difference: Unity Software Inc is far larger — about 2.5× TG Therapeutics Inc's market cap, and Unity Software Inc is more actively traded (15,432,191 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Unity Software Inc for 50 Days on average.
| TGTX | U | |
|---|---|---|
Market Cap | $8.16B | $20.20B |
Volume | 1,735,121 | 15,432,191 |
Sector | Health | Technology |
52-Week High | $59.06 | $49.47 |
52-Week Low | $26.94 | $17.13 |
Typical Hold Time | 16 Days | 50 Days |
Enterprise Value | $8.37B | $20.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Unity Software (U) trades at $46.77, up 2.93% with strong bullish momentum. The stock shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though still unprofitable. Technical indicators signal bullish sentiment with the current price near resistance at $47. Recent news highlights Meta VR partnership driving positive sentiment, while analyst consensus remains strongly bullish with 82.76% buy ratings.
Unity presents a growth opportunity with strategic partnerships and improving financial trends, but faces significant execution risks. The company's high valuation multiples and persistent losses require careful monitoring of profitability progress. Near-term catalysts include VR market expansion and advertising platform growth, though competitive pressures and macroeconomic uncertainty remain key concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
